GSK Lifts FY23 Outlook As Q3 Profit From Cont. Opns Surges

British drug major GSK Plc on Wednesday lifted its fiscal 2023 forecast for earnings and sales after reporting higher third-quarter profit on continuing operations basis. The results were benefited by vaccines' performance, mainly the US launch of Arexvy, the world's first RSV vaccine. Total profit for the quarter, meanwhile, plunged from last year on the absence of prior year's hefty gain.

from RTT - Top Story https://ift.tt/UaB9uLq
via IFTTT